Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | 2026-04-02 18:55:28 | 3.3 | -0.02 | -0.6 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRME | 0001894562 | Prime Medicine, Inc. | US74168J1016 | — | — | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 60 FIRST ST. | CAMBRIDGE | MA | 02141 | UNITED STATES | US | 617-465-0013 | 60 FIRST ST., CAMBRIDGE, MA, 02141 | 60 FIRST ST., CAMBRIDGE, MA, 02141 | — | Biotechnology | 2019 | Allan Reine | — | http://primemedicine.com | 238,759,057 | 180,514,014 | 180,552,179 | Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts. | 2026-04-02 17:45:29 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 238,759,057 | -57,973,251 | -19.5372 | 180,552,179 | 49,391,337 | 37.6571 |
| 2024 | 296,732,308 | -306,395,344 | -50.8011 | 131,160,842 | 11,221,595 | 9.3561 |
| 2023 | 603,127,652 | 603,127,652 | 100 | 119,939,247 | 22,693,420 | 23.3361 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Jeremy Duffield | Chief Scientific Officer | 2024 | 480,417 | 0 | — | 293,400 | 11,727 | 1,877,577 |
| Keith Gottesdiener | Chief Executive Officer, President | 2024 | 652,792 | 0 | — | 395,010 | 32,785 | 2,245,617 |
| Allan Reine | Chief Financial Officer | 2024 | 479,489 | 176,000 | — | 200,000 | 68,538 | 4,623,802 |
| Ann Lee | Chief Technical Officer | 2023 | 472,095 | 0 | — | 198,280 | 14,407 | 2,264,362 |
| Keith Gottesdiener | Chief Executive Officer, President | 2023 | 625,000 | 0 | — | 393,750 | 40,462 | 5,403,071 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 146 |
| 2024 | 214 |
| 2023 | 234 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 4,632,000 | 2,983,000 | 0 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 160,636,000 | 155,289,000 | 147,905,000 |
| General And Administrative Expenses | 52,346,000 | 50,161,000 | 43,387,000 |
| Operating Expenses | 212,982,000 | 205,450,000 | 204,792,000 |
| Operating Income | -208,350,000 | -202,467,000 | -204,792,000 |
| Net Income | -201,142,000 | -195,882,000 | -198,133,000 |
| Earnings Per Share Basic | -1.35 | -1.65 | -2.18 |
| Earnings Per Share Diluted | -1.35 | -1.65 | -2.18 |
| Weighted Average Shares Outstanding Basic | 148,758,527 | 118,600,381 | 90,969,327 |
| Weighted Average Shares Outstanding Diluted | 148,758,527 | 118,600,381 | 90,969,327 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 63,032,000 | 182,476,000 | 41,574,000 |
| Marketable Securities Current | 114,648,000 | 2,998,000 | 74,639,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 674,000 | 14,667,000 | 2,254,000 |
| Total Assets Current | 181,293,000 | 211,886,000 | 142,976,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 20,572,000 | 24,404,000 | 22,659,000 |
| Other Assets Non Current | 1,000,000 | 0 | 779,000 |
| Total Assets Non Current | 161,440,000 | 85,622,000 | 50,875,000 |
| Total Assets | 342,733,000 | 297,508,000 | 193,851,000 |
| Accounts Payable | 8,887,000 | 11,351,000 | 19,537,000 |
| Deferred Revenue | 7,824,000 | 7,092,000 | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 12,600,000 | 15,904,000 | 14,110,000 |
| Total Liabilities Current | 37,448,000 | 37,961,000 | 56,423,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 184,417,000 | 106,398,000 | 4,357,000 |
| Total Liabilities | 221,865,000 | 144,359,000 | 60,780,000 |
| Common Stock | 2,000 | 2,000 | 2,000 |
| Retained Earnings | -888,354,000 | -687,212,000 | -491,330,000 |
| Accumulated Other Comprehensive Income | 82,000 | 1,000 | -15,000 |
| Total Shareholders Equity | 120,868,000 | 153,149,000 | 133,071,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 7,321,000 | 6,128,000 | 4,653,000 |
| Share Based Compensation Expense | 29,268,000 | 26,068,000 | 13,910,000 |
| Other Non Cash Income Expense | — | 0 | -28,000 |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 996,000 | -5,257,000 | 9,140,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -162,564,000 | -122,865,000 | -165,412,000 |
| Purchases Of Marketable Securities | 205,413,000 | 129,449,000 | 104,951,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 4,531,000 | 7,294,000 | 8,724,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -108,763,000 | 68,457,000 | 18,711,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 38,081,000 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 151,512,000 | 195,876,000 | 655,000 |
| Change In Cash | -119,815,000 | 141,468,000 | -146,046,000 |
| Cash At End Of Period | 63,032,000 | 182,476,000 | 41,574,000 |
| Income Taxes Paid | — | — | 0 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.35 | -1.65 | -2.18 |
| Price To Earnings Ratio | -2.5704 | -1.7697 | -4.0642 |
| Earnings Growth Rate | -18.1818 | -24.3119 | -47.9714 |
| Price Earnings To Growth Ratio | 0.1414 | 0.0728 | 0.0847 |
| Book Value Per Share | 0.8125 | 1.2913 | 1.4628 |
| Price To Book Ratio | 4.2707 | 2.2613 | 6.0568 |
| Ebitda | -193,821,000 | -189,754,000 | -193,480,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 3,489,000 | 7,873,000 | 8,303,000 |
| Free Cash Flow | -166,053,000 | -130,738,000 | -173,715,000 |
| Return On Equity | -1.6641 | -1.279 | -1.4889 |
| One Year Beta | 1.9127 | 2.3995 | 1.7008 |
| Three Year Beta | 1.9601 | 1.8584 | 1.5601 |
| Five Year Beta | 1.8769 | 1.8584 | 1.5601 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Reine Allan | Director, Chief Executive Officer | 2026-02-26 | 1,300,000 | A | 1,300,000 |
| Alenson Carman | — | 2026-02-23 | 140,000 | A | 140,000 |
| LEE ANN L. | Chief Technical Officer | 2026-02-23 | 375,000 | A | 375,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 6,092,515 | 1,755,768 | 3.47 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 421,226 | 121,391 | 3.47 |
| PEAK6 LLC | 2025-12-31 | 856,743 | 246,900 | 3.47 |
| Corient Private Wealth LLC | 2025-12-31 | 134,556 | 38,777 | 3.47 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 134,275 | 38,696 | 3.47 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily S&P Biotech Bull 3X ETF | LABU | 124,530 | 474,459.3 | 0.0823 |
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 45,003 | 171,461.43 | 0.0124 |
| Pacer Funds Trust | 2026-01-31 | Pacer WealthShield ETF | PWS | 2,441 | 9,300.21 | 0.0296 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class P Shares | GSXPX | 242,769 | 924,949.89 | 0.0996 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R6 Shares | GTTUX | 242,769 | 924,949.89 | 0.0996 |